Anhedonia is a key symptom (and often risk factor) for various neuropsychiatric disorders, including depression, schizophrenia, substance use disorders, post-traumatic stress disorders, and Parkinson s Disease, among others. Across disorders, anhedonia has been associated with worse disease course, including poor response to pharmacological, psychological and neurostimulation treatments as well as completed suicide. Mounting evidence emerging from preclinical and translational sciences has clarified that  anhedonia  can be parsed into partially independent subcomponents, including incentive motivation, consummatory pleasure, reward learning, and effort-based decision making, pointing to distinct neurobiological substrates that could underlie anhedonic phenotypes. Taking an integrative approach that emphasizes cross-species integration and dimensional conceptualization of mental illnesses (e.g.